Earnings Release: Here's Why Analysts Cut Their Capgemini SE (EPA:CAP) Price Target To €161

Capgemini SE (EPA:CAP) shareholders are probably feeling a little disappointed, since its shares fell 8.7% to €104 in the week after its latest annual results. It was a credible result overall, with revenues of €22b and statutory earnings per share of €9.13 both in line with analyst estimates, showing that Capgemini is executing in line with expectations. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

earnings-and-revenue-growth
ENXTPA:CAP Earnings and Revenue Growth February 18th 2026

Following the latest results, Capgemini's 17 analysts are now forecasting revenues of €23.9b in 2026. This would be a satisfactory 6.2% improvement in revenue compared to the last 12 months. Statutory per share are forecast to be €9.41, approximately in line with the last 12 months. In the lead-up to this report, the analysts had been modelling revenues of €23.7b and earnings per share (EPS) of €9.87 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

See our latest analysis for Capgemini

The average price target fell 7.0% to €161, with reduced earnings forecasts clearly tied to a lower valuation estimate. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic Capgemini analyst has a price target of €208 per share, while the most pessimistic values it at €135. These price targets show that analysts do have some differing views on the business, but the estimates do not vary enough to suggest to us that some are betting on wild success or utter failure.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 6.2% growth on an annualised basis. That is in line with its 6.1% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 4.5% annually. So it's pretty clear that Capgemini is forecast to grow substantially faster than its industry.

Advertisement

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Capgemini. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Capgemini going out to 2028, and you can see them free on our platform here..

Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Capgemini that you should be aware of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:CAP

Capgemini

Provides consulting, digital transformation, technology, and engineering services primarily in North America, France, the United Kingdom, Ireland, the rest of Europe, the Asia-Pacific, and Latin America.

Undervalued with adequate balance sheet and pays a dividend.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1158.7% undervalued
32 users have followed this narrative
2 users have commented on this narrative
6 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.6% undervalued
49 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9220.2% undervalued
14 users have followed this narrative
0 users have commented on this narrative
7 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$1908.3% undervalued
11 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

JO
John_Eric
NOW logo
John_Eric on ServiceNow ·

The Company Nobody Brags About

Fair Value:US$266.0164.1% undervalued
30 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
A176750 logo
AnimalDoctorKwon on DuChemBIOLtd ·

DuChemBio absorbs Radio DNS Labs as Novartis injects 140B KRW into Korean RLT. With 100%+ OCF/EBITDA, the 6-mo lag is a de-risked steal.

Fair Value:₩10k43.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AL
NOW logo
Alice3D on ServiceNow ·

NOW is an established SAAS positioned for accelerated growth over the next 5 years.

Fair Value:US$15538.4% undervalued
23 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75029.1% undervalued
101 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6514.6% undervalued
69 users have followed this narrative
2 users have commented on this narrative
10 users have liked this narrative
BL
BlackGoat
CBRS logo
BlackGoat on Cerebras Systems ·

The Wafer Giant Threatening NVIDIA's GPU Hegemony

Fair Value:US$415.5449.5% undervalued
64 users have followed this narrative
3 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

ST
StoxEurope
AD logo
StoxEurope on Koninklijke Ahold Delhaize ·

I ran Ahold Delhaize through a three-model triangulation — DCF, dividend discount, and residual income — with every assumption published and tagged as fact or assumption. The interesting result isn't a number, it's a disagreement: the point estimates run from €20,03 (RIM) through €27,64 (DDM) to €64,91 (DCF), and the pairwise overlaps form two disjoint segments — €20,36–€21,54 and €39,60–€44,56. Between €21,54 and €39,60, no two of the three models agree. [img]https://staticm.fastcomments.com/1784197249786-1000x1000-ad-range-strip.png[/img] Most of the spread is lens properties rather than company drama. A dividend model structurally can't see the roughly half of shareholder returns Ahold pays through buybacks. The book is ~96 % goodwill from the 2016 merger, which pins the residual-income reading low. And ~83 % of the DCF's value sits beyond the explicit five years, so it leans hard on the terminal assumptions. Three honest lenses, three honest answers — the disagreement is the information. Disclosures Position disclosure: The author holds no position in Ahold Delhaize as at 9 July 2026. This valuation is a StoxEurope opinion, based on honest research. Mistakes are possible. This is not investment advice. Do your own research. This article demonstrates a valuation methodology. It is not an investment recommendation, is not personalised to any reader's circumstances, and every figure in it depends entirely on the stated assumptions

1
|
0